^
    22h
    Prevalence and prognostic impact of HPV, EBV, and HIV in head and neck squamous cell carcinoma in the Brazilian Amazon cohort. (PubMed, Clin Transl Oncol)
    TP53 and EGFR gene mutations were associated with more aggressive cancer phenotypes, leading to a 2.6-fold increase in the risk of death.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation
    1d
    PD-L1 in Oral Cavity Cancers-Audit for Tertiary Care Center in India. (PubMed, Indian J Surg Oncol)
    This is one of the first studies evaluating data on the expression of PDL-1 in oral cavity cancers in the Indian population and the factors affecting it. The data provides novel insights into many factors potentially affecting the expression of PDL-1 in oral cavity cancers and in the future, can be of help in developing treatment plans with various immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    1d
    Spatial Proteomics Reveals Layer-Specific Molecular Landscapes and KRT17-Mediated Inflammatory Crosstalk in Tongue Oral Lichen Planus. (PubMed, Br J Dermatol)
    Our study uncovers layer-specific molecular landscapes in tongue OLP and identifies KRT17 as a candidate implicated in immune-epithelial crosstalk, providing novel insights into pathogenesis and a potential direction for future therapeutic exploration.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • ASS1 (Argininosuccinate synthase 1) • KRT17 (Keratin 17) • IL1B (Interleukin 1, beta) • PHGDH (Phosphoglycerate Dehydrogenase) • IL16 (Interleukin 16) • RAC2 (Rac Family Small GTPase 2)
    1d
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    1d
    MACS: Mental Health App for Cancer Survivors Study (clinicaltrials.gov)
    P=N/A, N=1, Terminated, University of Wisconsin, Madison | Active, not recruiting --> Terminated; App developer is no longer in business
    Trial termination
    1d
    Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=7, Completed, Godavari Biorefineries Limited | Not yet recruiting --> Completed | N=27 --> 7 | Trial completion date: Jan 2023 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    1d
    SUSPECT2: Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=90, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Jan 2026
    Enrollment closed • Trial primary completion date
    1d
    Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (clinicaltrials.gov)
    P2, N=50, Completed, Yale University | Active, not recruiting --> Completed
    Trial completion
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    1d
    Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC. (PubMed, Arch Biochem Biophys)
    Furthermore, GAB2 overexpression reversed these effects and desensitized cisplatin by activating NF-κB-mediated JNK suppression. Overall, cisplatin actively remodels the OCT1-DNMT1-piR-hsa-30937 axis by regulating piRNA expression, which in turn potentiates cisplatin cytotoxicity by attenuating GAB2-mediated survival signaling in OSCC.
    Journal
    |
    DNMT1 (DNA methyltransferase 1) • SLC22A1 (Solute Carrier Family 22 Member 1)
    |
    cisplatin
    1d
    PBM: A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Peter MacCallum Cancer Centre, Australia
    New trial
    2d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (clinicaltrials.gov)
    P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    2d
    Interventional effects of mesenchymal stem cells on epithelial-mesenchymal transition in head and neck squamous cell carcinoma and underlying mechanisms: a systematic review and meta-analysis of in vitro studies. (PubMed, Front Immunol)
    The existing in vitro evidence suggests that mesenchymal stem cells may exhibit a potential to promote EMT in HNSCC, potentially regulating tumor progression through multiple signaling pathway networks and providing new potential targets for future therapies targeting the TME. However, more high-quality, standardized in vivo and in vitro studies are needed to further validate the related mechanisms and therapeutic potential.
    Clinical • Preclinical • Retrospective data • Review • Journal
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • IL6R (Interleukin 6 receptor) • CXCR2 (Chemokine (C-X-C motif) receptor 2)